Details of the Drug Combination

General Information of Drug Combination (ID: DC6CWYI)

Drug Combination Name
Sarpogrelate MK-4815
Indication
Disease Entry Status REF
DD2 Investigative [1]
Component Drugs Sarpogrelate   DMGLP6S MK-4815   DMT9K74
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DD2
Zero Interaction Potency (ZIP) Score: 9.998
Bliss Independence Score: 13.41
Loewe Additivity Score: 4.911
LHighest Single Agent (HSA) Score: 4.635

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sarpogrelate
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [2]
Sarpogrelate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Antagonist [4]
------------------------------------------------------------------------------------
Indication(s) of MK-4815
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Investigative [3]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Hepatoblastoma DC5GAUN HB3 Investigative [5]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 210).
3 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
4 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
5 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976